NCT01588847

Brief Summary

Studies in animals and retrospective studies in humans show that regional anesthesia reduces metastatic cancer dissemination. The investigators hypothesize that in patients suffering from malignant melanoma who have to undergo radical inguinal lymph node dissection immune function will be less compromised and long term survival will be superior when spinal anesthesia is compared to general anesthesia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
230

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

March 13, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 1, 2012

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2019

Completed
Last Updated

December 11, 2014

Status Verified

December 1, 2014

Enrollment Period

7 years

First QC Date

March 13, 2012

Last Update Submit

December 10, 2014

Conditions

Keywords

perioperative immunoeditingpotential predictive biomarkerslymph node dissection

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    five years

Secondary Outcomes (6)

  • Changes of the total amount of immune cells

    15 minutes before end of surgery

  • Changes of the total amount of immune cells

    24 hours postoperatively

  • Changes of the total amount of immune cells

    Five days postoperatively

  • Potential predictive biomarkers

    15 minutes before end of surgery

  • Potential predictive biomarkers

    24 hours postoperatively

  • +1 more secondary outcomes

Study Arms (2)

Regional anesthesia

EXPERIMENTAL
Procedure: Spinal anesthesia with Bupivacaine hyperbar 0.5 %

General anesthesia

ACTIVE COMPARATOR
Procedure: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane

Interventions

Spinal anesthesia with Bupivacaine hyperbar 0.5 %

Also known as: Regional anesthesia
Regional anesthesia

General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane

Also known as: General anesthesia
General anesthesia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled for inguinal lymph node dissection because of malignant melanoma of the lower limb
  • Signed informed consent

You may not qualify if:

  • Age \< 18 years
  • Female patients who are pregnant or nursing
  • Multiple organ failure
  • Contraindications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fachklinik Hornheide, Department of Anesthesiology, Intensive Care and Pain Therapy

Münster, D-48157, Germany

RECRUITING

MeSH Terms

Conditions

Melanoma

Interventions

Anesthesia, SpinalAnesthesia, ConductionAnesthesia, GeneralSufentanilPropofolRocuroniumSevoflurane

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

AnesthesiaAnesthesia and AnalgesiaFentanylPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsAndrostanolsAndrostanesSteroidsFused-Ring CompoundsPolycyclic CompoundsMethyl EthersEthersHydrocarbons, FluorinatedHydrocarbons, Halogenated

Study Officials

  • Hugo K Van Aken, MD PhD

    University Hospital Muenster, Department of Anesthesia, Intensive Care and Pain Therapy

    STUDY CHAIR

Central Study Contacts

Gerhard Brodner, Prof. Dr.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 13, 2012

First Posted

May 1, 2012

Study Start

March 1, 2012

Primary Completion

March 1, 2019

Study Completion

March 1, 2019

Last Updated

December 11, 2014

Record last verified: 2014-12

Locations